Hosted on MSN7m
Non-Opioid Pain Medication Journavx Gets FDA Approval
The Food and Drug Administration has approved a first-of-its-kind non-opioid pain medication, providing a new option for ...
Des Moines Register10m
FDA upgrades Oregon, Washington recall for Lay's Classic Potato Chips to highest level
The FDA classification affects the Dec. 16 limited recall by Frito-Lay for 6,344 of its 13-ounce bags of Lay’s Classic Potato ...
Live Science25m
FDA approves 1st new class of opioid-free painkillers in over 20 years
The FDA has approved Journavx, an oral medication for treating pain that doesn't target the brain like addictive opioids.
JD Supra25m
FDA Bans Red Dye No. 3 in Food and Ingested Drugs: What Manufacturers Should Know
On January 16, 2025, the Food and Drug Administration (FDA) issued an order banning FD&C Red No.3 in food and ingested drugs.1 Food and ingested ...
Hosted on MSN39m
AI Can Help Spot Congenital Heart Defects
Artificial intelligence (AI) can help doctors detect fetal heart defects, improving newborns' chances of survival, a new ...
aha.org54m
FDA approves first-in-class non-opioid painkiller
The Food and Drug Administration Jan. 30 announced it approved Journavx (suzetrigine) oral tablets, a first-in-class ...
aha.org56m
CISA, FDA warn of vulnerabilities in Contec patient monitors
The Cybersecurity and Infrastructure Security Agency and Food and Drug Administration Jan. 30 released notices warning of ...
FDA approved the first new kind of pain medication in 27 years. Here’s how it works
The FDA just approved a new type of pain medication, and it's a non-opioid called suzetrigine that stops body pain at its ...
Chocolate Recall Updated to Highest Risk Level, FDA Warns Consumption Could Cause Death
Cal Yee Farms' dark chocolate walnuts, dark chocolate almonds and dark chocolate apricots have been given a Class 1 recall ...
Healio1h
FDA approves nonopioid Journavx for moderate to severe acute pain
The FDA has approved Journavx 50 mg oral tablets for the treatment of moderate to severe acute pain in adults, according to a ...
The American Journal of Managed Care1h
FDA Approves Celltrion’s Tocilizumab-anoh, Biosimilar to Actemra
Avtozma, the third biosimilar to Actemra, has received FDA approval for multiple inflammatory diseases and COVID-19, potentially expanding treatment access for patients.
Live Science1h
FDA approves 'ketamine' nasal spray for depression — here's everything you need to know
A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with severe depression, the FDA says. Here's what that means.